Division of Community Internal Medicine, Mayo Clinic, Jacksonville, FL 32224.
Rom J Intern Med. 2022 Mar 17;60(1):14-23. doi: 10.2478/rjim-2021-0031. Print 2022 Mar 1.
The treatment of diabetes mellitus type 2 (DM2) is becoming more complex as new medications are approved. Primary care providers must maintain their medical knowledge on emerging medications for best patient care. This review simplifies the non-insulin treatments of diabetes with an emphasis on the cardio-renal protectants, sodium-glucose cotransporter 2 (SGLT-2) inhibitors and glucagon-like peptide 1 receptor agonists (GLP-1).
随着新药物的批准，2 型糖尿病（DM2）的治疗变得更加复杂。初级保健提供者必须保持对新兴药物的医学知识，以实现最佳患者护理。本综述简化了糖尿病的非胰岛素治疗，重点介绍了心脏肾保护剂、钠-葡萄糖共转运蛋白 2（SGLT-2）抑制剂和胰高血糖素样肽 1 受体激动剂（GLP-1）。
